Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATYR aTyr Pharma	$5.38 +0.6%	$5.30	$1.67 ▼ $7.29	$527.17M	1.01	3.82 million shs	4.67 million shs
IVA Inventiva	$6.19 -2.5%	$3.65	$1.53 ▼ $6.50	$592.15M	0.68	56,904 shs	189,339 shs
PFSCF ProMetic Life Sciences	$5.47	$5.47	$5.47 ▼ $352.00	$127.45M	2.46	279 shs	N/A
TECX Tectonic Therapeutic	$25.54 -0.1%	$22.45	$13.70 ▼ $61.07	$477.91M	3.42	183,634 shs	80,247 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATYR aTyr Pharma	0.00%	+0.56%	+13.98%	+21.44%	+190.81%
IVA Inventiva	0.00%	+38.48%	+87.01%	+97.70%	+158.46%
PFSCF ProMetic Life Sciences	0.00%	0.00%	0.00%	0.00%	0.00%
TECX Tectonic Therapeutic	0.00%	-2.44%	+15.10%	+18.74%	+34.78%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATYR aTyr Pharma	2.0299 of 5 stars	3.6	1.0	0.0	0.0	2.1	1.7	0.6
IVA Inventiva	2.9947 of 5 stars	3.4	5.0	0.0	0.0	2.0	1.7	0.6
PFSCF ProMetic Life Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TECX Tectonic Therapeutic	2.3075 of 5 stars	3.6	0.0	0.0	0.0	2.3	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATYR aTyr Pharma	3.17	Buy	$23.25	332.16% Upside
IVA Inventiva	2.83	Moderate Buy	$13.00	110.02% Upside
PFSCF ProMetic Life Sciences	0.00	N/A	N/A	N/A
TECX Tectonic Therapeutic	3.17	Buy	$80.33	214.54% Upside

Current Analyst Ratings Breakdown

Latest PFSCF, ATYR, IVA, and TECX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2025	IVA Inventiva	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$26.00
8/27/2025	IVA Inventiva	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$26.00
8/22/2025	ATYR aTyr Pharma	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $17.00
7/21/2025	TECX Tectonic Therapeutic	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$64.00
6/20/2025	ATYR aTyr Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$17.00 ➝ $25.00
6/11/2025	TECX Tectonic Therapeutic	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$76.00
6/6/2025	TECX Tectonic Therapeutic	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$87.00
6/5/2025	TECX Tectonic Therapeutic	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/4/2025	ATYR aTyr Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00

(Data available from 8/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATYR aTyr Pharma	$230K	2,292.11	N/A	N/A	$0.83 per share	6.48
IVA Inventiva	$9.95M	59.51	N/A	N/A	($1.21) per share	-5.12
PFSCF ProMetic Life Sciences	$36.55M	3.49	N/A	N/A	($67.63) per share	-0.08
TECX Tectonic Therapeutic	N/A	N/A	N/A	N/A	$9.54 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATYR aTyr Pharma	-$64.02M	-$0.80	N/A	N/A	N/A	-93.69%	-68.83%	11/6/2025 (Estimated)
IVA Inventiva	-$199.34M	N/A	N/A	N/A	N/A	N/A	N/A	9/25/2025 (Estimated)
PFSCF ProMetic Life Sciences	-$150.73M	N/A	∞	N/A	-894.02%	-3,350.55%	-67.76%	N/A
TECX Tectonic Therapeutic	-$57.98M	-$4.04	N/A	N/A	N/A	-30.13%	-28.33%	11/6/2025 (Estimated)

Latest PFSCF, ATYR, IVA, and TECX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/25/2025	Q2 2025	IVA Inventiva	-$0.41	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	ATYR aTyr Pharma	-$0.18	-$0.22	-$0.04	-$0.22	N/A	N/A
8/7/2025	Q2 2025	TECX Tectonic Therapeutic	-$0.98	-$1.07	-$0.09	-$1.07	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATYR aTyr Pharma	N/A	N/A	N/A	N/A	N/A
IVA Inventiva	N/A	N/A	N/A	N/A	N/A
PFSCF ProMetic Life Sciences	N/A	N/A	N/A	N/A	N/A
TECX Tectonic Therapeutic	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATYR aTyr Pharma	0.01	5.63	5.63
IVA Inventiva	N/A	0.92	0.92
PFSCF ProMetic Life Sciences	N/A	0.95	0.71
TECX Tectonic Therapeutic	N/A	25.60	25.60

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATYR aTyr Pharma	61.72%
IVA Inventiva	19.06%
PFSCF ProMetic Life Sciences	0.10%
TECX Tectonic Therapeutic	62.63%

Insider Ownership

Company	Insider Ownership
ATYR aTyr Pharma	3.70%
IVA Inventiva	32.00%
PFSCF ProMetic Life Sciences	N/A
TECX Tectonic Therapeutic	9.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATYR aTyr Pharma	53	97.99 million	94.36 million	Optionable
IVA Inventiva	100	95.66 million	65.05 million	Not Optionable
PFSCF ProMetic Life Sciences	50	23.31 million	N/A	Not Optionable
TECX Tectonic Therapeutic	120	18.71 million	16.99 million	N/A

PFSCF, ATYR, IVA, and TECX Headlines

Recent News About These Companies

Tectonic Therapeutic to Participate in September Investor Conferences

August 28 at 9:00 AM | globenewswire.com

Tectonic Therapeutic, Inc. (NASDAQ:TECX) Receives Average Recommendation of "Buy" from Brokerages

August 24, 2025 | marketbeat.com

15,369 Shares in Tectonic Therapeutic, Inc. $TECX Acquired by Cliffwater LLC

August 20, 2025 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Has $614,000 Stock Position in Tectonic Therapeutic, Inc. $TECX

August 20, 2025 | marketbeat.com

40,000 Shares in Tectonic Therapeutic, Inc. (NASDAQ:TECX) Bought by Knott David M Jr

August 12, 2025 | marketbeat.com

Tectonic Therapeutic (NASDAQ:TECX) Releases Quarterly Earnings Results, Misses Expectations By $0.09 EPS

August 11, 2025 | marketbeat.com

Tectonic Therapeutic Reports Q2 Financial Results

August 9, 2025 | theglobeandmail.com

Tectonic (TECX) Q2 R&D Soars 142%

August 7, 2025 | fool.com

Tectonic Therapeutic Announces Second Quarter 2025 Financial Results and Recent Business Highlights

August 7, 2025 | manilatimes.netM

Tectonic Therapeutic (TECX) to Release Quarterly Earnings on Wednesday

August 7, 2025 | marketbeat.com

Y Intercept Hong Kong Ltd Makes New $234,000 Investment in Tectonic Therapeutic, Inc. (NASDAQ:TECX)

August 1, 2025 | marketbeat.com

Tectonic Therapeutic, Inc. Added to Russell 3000® Index Following Annual Reconstitution - Nasdaq

July 1, 2025 | nasdaq.com

Tectonic Therapeutic joins Russell 3000 index

June 30, 2025 | msn.com

Tectonic Therapeutic, Inc. Added to Russell 3000® Index Following Annual Reconstitution

June 30, 2025 | quiverquant.comQ

Tectonic Therapeutic Joins Russell 3000® Index

June 30, 2025 | globenewswire.com

Raymond James Resumes Coverage of Tectonic Therapeutic (TECX) With an Outperform Rating

June 25, 2025 | msn.com

We Think Tectonic Therapeutic (NASDAQ:TECX) Can Afford To Drive Business Growth

June 15, 2025 | finance.yahoo.com

Tectonic Therapeutics (TECX) Gains Outperform Rating from Raymond James | TECX Stock News

June 10, 2025 | gurufocus.com

LifeSci Capital Initiates Coverage of Tectonic Therapeutic (TECX) with Outperform Recommendation

June 7, 2025 | msn.com

Tectonic Therapeutic Holds 2025 Annual Stockholders Meeting

June 6, 2025 | tipranks.com

Tectonic Therapeutic (TECX) Receives Outperform Rating and $87 Price Target | TECX Stock News

June 5, 2025 | gurufocus.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PFSCF, ATYR, IVA, and TECX Company Descriptions

aTyr Pharma NASDAQ:ATYR

$5.38 +0.03 (+0.56%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$5.46 +0.08 (+1.39%)

As of 08/29/2025 07:59 PM Eastern

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Inventiva NASDAQ:IVA

$6.19 -0.16 (-2.52%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$6.24 +0.05 (+0.81%)

As of 08/29/2025 07:23 PM Eastern

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

ProMetic Life Sciences OTCMKTS:PFSCF

$5.47 0.00 (0.00%)

As of 11/18/2019

Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.

Tectonic Therapeutic NASDAQ:TECX

$25.54 -0.03 (-0.12%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$25.62 +0.07 (+0.29%)

As of 08/29/2025 04:10 PM Eastern

Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time